Filing Flows › LifeStance Health Group (LFST) › Q3 2026 › vs Q3 2025
LifeStance Health Group (LFST) Q3 2026 vs Q3 2025 (year over year)
LifeStance Health Group's revenue rose $92.1M (+25%) from $364M in Q3 2025 to $456M in Q3 2026. Operating margin 7.3% against 2.0% (+5.2 pts).
LifeStance Health Group, Q3 2026: revenue $456M (+25% year over year), operating margin 7.3%, net earnings $22.4M, operating cash flow $37.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.3% | 2.0% | +5.2 pts |
| Net margin | 4.9% | 0.3% | +4.6 pts |
| Free cash flow margin | 4.9% | 4.7% | +0.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $456M | $364M | $92.1M | +25% |
| Operating profit | $33.1M | $7.4M | $25.7M | +346% |
| Costs & expenses | $423M | $356M | $66.4M | +19% |
| Pre-tax earnings | $27.4M | $4.6M | $22.8M | +499% |
| Other expense, net | $5.7M | $2.8M | $2.8M | +100% |
| SG&A | $113M | $95.6M | $17.8M | +19% |
| Other operating costs | $309M | $261M | $48.6M | +19% |
| Net earnings | $22.4M | $1.1M | $21.3M | 21× |
| Income tax | $5.0M | $3.5M | $1.5M | +44% |
| Depreciation & amortization | $12.1M | $10.3M | $1.7M | +17% |
| Share-based compensation | $18.2M | $18.3M | −$129K | -0.7% |
| Working capital & other | $15.6M | $2.4M | $13.2M | +541% |
| Operating cash flow | $37.0M | $27.3M | $9.7M | +36% |
| Free cash flow (OCF − capex) | $22.4M | $17.0M | $5.4M | +32% |
| Capital expenditures | $14.7M | $10.3M | $4.4M | +42% |
Questions
How much did LifeStance Health Group's revenue grow year over year in Q3 2026?
LifeStance Health Group's revenue rose $92.1M (+25%) from $364M in Q3 2025 to $456M in Q3 2026. Operating margin 7.3% against 2.0% (+5.2 pts).